Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Generated: May 29, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,393,529

« Back to Dashboard

Summary for Patent: 5,393,529

Title: Estrogen-containing active substance plaster
Abstract:The present invention relates to active substance plasters for the controlled release of active substances to the skin consisting of a backing layer, an adhesive film connected therewith which film is water-soluble and consists of pressure-sensitive adhesive which comprises water-swellable polymers and in which the active substance is at least partially soluble, and of a removable protective layer covering the adhesive film, in which plasters the pressure-sensitive adhesive is based on homo and/or copolymers with at least one derivative of the acrylic or methacrylic acid, and which comprise as active substances, partially or completely dissolved in the adhesive, at a concentration of 0.5 to 10.0%-wt estrogens and their pharmaceutically acceptable derivatives alone or in combination with gestagens.
Inventor(s): Hoffmann; Hans-Rainer (Neuwied, DE), Klein; Robert P. (Neuwied, DE), Meconi; Reinhold (Neuwied, DE), Cordes; Gunter (Leichingen, DE), Wolff; Hans M. (Monheim, DE)
Assignee: LTS Lohmann Therapie-Systeme GmbH & Co. KG (Neuweid, DE) Schwarz Pharma AG (Monheim, DE)
Application Number:08/074,698
Patent Claim Types:
see list of patent claims

No matches for this query

Foreign Priority and PCT Information for Patent: 5,393,529

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany3933460Oct 06, 1989

International Patent Family for Patent: 5,393,529

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria126069► Subscribe
Australia6312890► Subscribe
Australia637637► Subscribe
Canada2027053► Subscribe
Czechoslovakia9004859► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus